Efficacy

Polivy (polatuzumab vedotin-piiq) Efficacy in Treating Lymphoma

Polivy (polatuzumab vedotin-piiq) is a monoclonal antibody-drug conjugate that has shown efficacy in the treatment of certain types of lymphoma, specifically diffuse large B-cell lymphoma (DLBCL). It targets the protein CD79b, which is found on the surface of B cells, and delivers a cytotoxic agent directly to these cells. Polivy is used in combination with bendamustine and a rituximab product (a regimen known as "BR") for the treatment of adult patients with relapsed or refractory DLBCL, not otherwise specified, after at least two prior therapies. Clinical trials have demonstrated that this combination can lead to improved response rates and survival outcomes compared to treatment with BR alone.

In a pivotal phase II study, patients treated with Polivy combined with BR showed a complete response rate of 40%, which is significant given the poor prognosis of relapsed or refractory DLBCL. The median duration of response for those who achieved a complete response was also notably extended, indicating a potential for long-term benefit in a subset of patients. These results support the use of Polivy as an effective treatment option for patients with this challenging form of lymphoma.

Epkinly (epcoritamab-bysp) Efficacy in Treating Lymphoma

Epkinly (epcoritamab-bysp) is an investigational bispecific antibody designed to target CD20, a protein expressed on the surface of B-cells, and CD3, a protein present on T-cells. By engaging both B and T cells, Epkinly is intended to promote the body's immune response against malignant B cells. While still under clinical investigation, preliminary data from early-phase trials suggest that Epkinly could be a promising therapeutic option for the treatment of B-cell non-Hodgkin lymphoma, including DLBCL and follicular lymphoma.

Early clinical trials have reported encouraging response rates in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The efficacy of Epkinly is being evaluated in terms of overall response rate, duration of response, and progression-free survival, among other measures. As clinical development progresses, additional data will be necessary to fully establish the safety and efficacy profile of Epkinly for the treatment of lymphoma. However, the initial results are promising and suggest that Epkinly may offer a novel therapeutic mechanism for patients with this type of cancer.